Skip to main content
Equibles
AZR logo

AZR · Azora Therapeutics, Inc. (DE)

Track AZR — free

Use AZR with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AZR.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$4.00 +0.29 (+7.82%) At close · Nov 6
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“the Company has concluded that there is substantial doubt about its ability to continue as a going concern.”
View the 10-Q filed Aug 14, 2026
Market Cap
$10.50M
Shares
2.63M
Volume · Nov 6 78.19K Avg daily vol (3M) 52.9K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$4.00 Open$3.91 Day$3.76–4.00 52W close$1.36–8.25 Avg vol 30d44K Short vol18% Last earningsNov 15, 2022 DataJan 2020–Nov 2026 Filing10-Q · Aug 14

Latest documents

2026
Oct 21
Quarterly report 10-Q/A FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2

Adial acquired Azora Therapeutics, received approximately $24.3 million net in initial financing proceeds, and targets AT177 IND and Phase 1a initiation in first half of 2027; recurring losses raise substantial doubt about its going concern.

Net loss $51.99M Diluted EPS -$11.25
Read from the MD&A section
Oct 21
Registration statement S-3/A
Registration statement

Adial Pharmaceuticals, Inc. registers proposed resale of 25,148,970 common shares by selling stockholders, tied to its Azora acquisition and related PIPE and noteholder warrants. Stockholder approval is required by December 11, 2026, or significant cash payments could be owed.

Read from the first part of this long document
Oct 16
Proxy statement DEFA14A
Proxy statement

Adial Pharmaceuticals, Inc. disclosed that its 2026 Annual Meeting was further adjourned on October 15, 2026 with respect to Proposals 3, 4, 5 and 6, pending approval of its Listing Application, and will reconvene on October 26, 2026.

Oct 16
Current report 8-K Events of Oct 15
Other events

Adial Pharmaceuticals further adjourned its 2026 Annual Meeting on October 15, 2026 with respect to Proposals 3, 4, 5 and 6 because Nasdaq had not approved the Listing Application; polls remain open and the meeting will reconvene on October 26, 2026 at 8:30 a.m. Eastern Time.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$57.80M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$28.71M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+987.7%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
—
Latest settlement
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Bearish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 25.6 · fear Equity put/call 0.59
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +26%
above
Price vs 50-day avg −11%
below
RSI (14) 49
neutral
MACD trend Positive
52-week position 38%
mid-range
Volume (OBV) Bearish div.
distributing
Momentum
relative strength
Strong
1-month return +3%
trailing
6-month return +148%
trailing
YTD return −27%
this year
Relative strength +149%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $5 › 200d $3 — 50d above 200d
Institutional flow Distributing
8 of 17 funds reported for Sep 30 · net -4.6K sh shares · +2 new
Insider flow Flat
No net insider activity over 90 days
Short interest Flat
No short-interest data
Volume signal Normal
Volume near normal
Institution breadth Steady
17 holders — mid 3-yr range
Fundamentals
Strong
EPS growth +82%
Y/Y
Free cash flow $-6.6M
Balance sheet $5.9M
net cash
Quant / Vol
risk profile
Very High
Volatility 112%
annualized · 1-yr
Max drawdown −84%
past year
ATR 15.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
2 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+26% Bullish
Price vs 50-day avg
−11% Bearish
RSI (14)
49 Neutral
MACD trend
Positive Bullish
52-week position
38% Neutral
Volume (OBV)
Bearish div. Bearish
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross) No cross
50d $5 › 200d $3 — 50d above 200d
Institutional flow Distributing
8 of 17 funds reported for Sep 30 · net -4.6K sh shares · +2 new
Insider flow Flat
No net insider activity over 90 days
Short interest Flat
No short-interest data
Volume signal Normal
Volume near normal
Institution breadth Steady
17 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $4 · 38% Range high $8
vs 200-day avg +26% vs 50-day avg -11%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
AZR
Azora Therapeutics, Inc. (DE)
this stock
$10.50M — — — 6.8%
VRTX
Vertex Pharmaceuticals Inc
 $138.71B +20.7% +46.2% 35.2 1.7%
MRNA
Moderna, Inc.
 $101.48B +762.0% +4.3% — 8.2%
REGN
Regeneron Pharmaceuticals, Inc.
 $93.82B +17.2% +20.8% 20.1 2.1%
CSLLY
Csl Ltd
 $66.72B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
18
% held
5.0%
Reported
8 of 17
Top holder
JANE STREET GROUP, LLC
Held Float
View
Short & Settlement
Short Volume
Short vol %
18%
As of
Nov 6, 2026
Short Total
View
Financials
Financials
Net income (FY)
$-8.0M
EPS diluted
$-11.93
View
Buybacks
Authorized
shares 26.7K
Remaining
shares 13.3K
Spent Remaining
View
Filings
SEC Filings
Latest
8-K
Filed
Oct 28, 2026
This year
33

Azora Therapeutics appointed Matthew Davidson as CEO, Celia Economides as CFO and Julie Saiki as chief strategy officer. Stockholders increased authorized shares from 100,000,000 to 500,000,000 and approved preferred-stock conversion; Nasdaq trading is expected under “AZR” on October 29, 2026.

View
Exempt Offerings
Offering
$4.3M
Filed
Dec 3, 2025
View
Earnings & Events
Webcasts
Last webcast
Jun 11, 2026
View
Investor Relations
Latest news
Adial Pharmaceuticals Announces N…
Published
Oct 28, 2026
View

Performance

5D 20D 120D MTD YTD
AZR +5.0% +2.6% +148.5% +5.0% -27.3%
SPY -2.7% -5.6% -0.5% -2.7% +7.8%
vs SPY +7.7% +8.1% +148.9% +7.7% -35.1%

Capital returns

Buyback program · as of Dec 31, 2023
Authorized
shares 26,665
Spent (derived)
shares 13,330
Remaining
shares 13,335
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1513525 13F (30d) 10 filings 7 filers Visit website Investor relations